Etodolac Articles
Nippon Shinyaku profit up 12% on IP turnover
5 June 2009
Japan stock market week to Feb 19, 2007
26 February 2007
UK parliament
28 January 2002
Gore blunders on drugs, dog and mother-in-law
19 September 2000
AHP posts healthy 2nd quarter results
24 July 2000
AHP posts 18% net income growth
20 April 2000
Ranbaxy seeks partner to develop asthma molecule
22 March 2000
Stock Commentary Tokyo
8 April 1999
Stock Commentary New York
10 December 1998
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
American Home Pharma Sales Up 7% For 2nd Qtr
22 July 1998
US Quarterly Financial Results Round-Up
23 April 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
Roberts Receives Rights To Wyeth's Lodine In UK And Ireland
13 January 1997
W-A's Lodine XL Approved In USA
4 November 1996
US NAPM Slams "Pediatric Research" Patent Extensions Plans
14 October 1996
American Home's Patent Deal Stalls US Health Bill
12 August 1996
US Senate Votes Against Ending GATT Loopholes
8 July 1996
Etodolac Cleared For Rheumatoid Arthritis
8 July 1996
Strong Growth At AHP At Start Of 1996
6 May 1996
Disease ManagementThe Way Forward
15 May 1995
Etodolac Comarketing Agreement
3 October 1994
ETODOLAC AND GI INJURY
23 May 1994
MIGRAINE MARKET SET TO BLOSSOM
21 February 1994
MUSCULOSKELETAL MARKET TO DECLINE
6 December 1993
US 3rd QTR RESULTS MIXED AS DRUG IND CUTS BACK
25 October 1993
LODINE IN HIGHER STRENGTH
23 August 1993
AMERICAN HOME HAS CONFIDENCE FOR 1993
12 April 1993
AMERICAN HOME: FINALLY A PHARMA COMPANY
7 December 1992
ANALYST'S ESTIMATES OF US THIRD QTR EARNINGS
12 October 1992
AMERICAN HOME ISA "STRONG BUY"
18 May 1992
IMPROVEMENTS IN 1ST QTR FOR US FIRMS
20 April 1992
US NEW PRESCRIPTI0N DRUG SALES IN 1991
13 April 1992
ABBOTT, AHP STRONG 4th QTR RESULTS
20 January 1992
DECEMBER US APPROS REVIEWED
20 January 1992
US FDA BEATS 1990 DRUG APPROVALS IN 1991
13 January 1992
Showing 1-45 of 45 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
